AstraZeneca: progress against ovarian cancer
(CercleFinance.com) - On Saturday AstraZeneca announced that the combination of Lynparza and Imfinzi reduced the risk of disease progression or death by 37% compared to chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumour BRCA mutations in the DUO-O phase III trial.
Susan Galbraith, executive vice president of oncology R&D at AstraZeneca, said that the DUO-O trial demonstrates the potential of combining PARP inhibition with immunotherapy and we look forward to seeing more mature data and key secondary endpoint results.
In a planned exploratory analysis of the HRD-negative subgroup of patients, Lynparza, Imfinzi, chemotherapy and bevacizumab reduced the relative risk of disease progression or death by 32% compared with chemotherapy and bevacizumab. Median progression-free survival was 20.9 months versus 17.4 months.
At the time of this interim analysis, an additional arm evaluating the combination of chemotherapy and bevacizumab was being evaluated.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Susan Galbraith, executive vice president of oncology R&D at AstraZeneca, said that the DUO-O trial demonstrates the potential of combining PARP inhibition with immunotherapy and we look forward to seeing more mature data and key secondary endpoint results.
In a planned exploratory analysis of the HRD-negative subgroup of patients, Lynparza, Imfinzi, chemotherapy and bevacizumab reduced the relative risk of disease progression or death by 32% compared with chemotherapy and bevacizumab. Median progression-free survival was 20.9 months versus 17.4 months.
At the time of this interim analysis, an additional arm evaluating the combination of chemotherapy and bevacizumab was being evaluated.
Copyright (c) 2023 CercleFinance.com. All rights reserved.